ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

• Main Authors: Hymowitz, Sarah G., Jin, Sha, Khaw, Seong Lin, Kovar, Peter J., Lam, Lloyd T., Lee, Jackie, Maecker, Heather L., Marsh, Kennan C., Mason, Kylie D., Mitten, Michael J., Sampath, Deepak, Nimmer, Paul M., Oleksijew, Anatol, Park, Chang H., Park, Cheol-Min, Phillips, Darren C., Roberts, Andrew W., Seymour, John F., Smith, Morey L., Sullivan, Gerard M., Tahir, Stephen K., Wendt, Michael D., Xiao, Yu, Xue, John C., Zhang, Haichao, Humerickhouse, Rod A., Rosenberg, Saul H., Elmore, Steven W., Tse, Chris, Souers, Andrew J., Leverson, Joel D., Boghaert, Erwin R., Ackler, Scott L., Catron, Nathaniel D., Chen, Jun, Dayton, Brian D., Ding, Hong, Enschede, Sari H., Fairbrother, Wayne J., Huang, David C. S.
• 其他作者: School of Physical and Mathematical Sciences
• 格式: Article
• 語言: English
• 出版: 2013
• 主題: DRNTU::Science::Chemistry::Biochemistry
• 在線閱讀: https://hdl.handle.net/10356/107357; http://hdl.handle.net/10220/18024; http://dx.doi.org/10.1038/nm.3048

Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of dir...